These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 21938451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
    Migliore A, Bizzi E, Broccoli S, Laganà B.
    Clin Rheumatol; 2012 Jan; 31(1):193-4. PubMed ID: 22005889
    [No Abstract] [Full Text] [Related]

  • 3. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
    Migliore A, Bizzi E, Broccoli S, Laganà B.
    Clin Rheumatol; 2012 Jan; 31(1):133-7. PubMed ID: 21701796
    [Abstract] [Full Text] [Related]

  • 4. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [Abstract] [Full Text] [Related]

  • 5. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.
    J Med Econ; 2013 Feb; 16(4):479-89. PubMed ID: 23339434
    [Abstract] [Full Text] [Related]

  • 6. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT, Adorni G.
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [Abstract] [Full Text] [Related]

  • 7. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, López-Vallejo JF.
    J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
    [Abstract] [Full Text] [Related]

  • 8. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P, Wendling D, Cohen JD.
    Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [Abstract] [Full Text] [Related]

  • 9. Psoriatic arthritis.
    Goupille P.
    Joint Bone Spine; 2005 Dec; 72(6):466-70. PubMed ID: 16310398
    [Abstract] [Full Text] [Related]

  • 10. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L.
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [Abstract] [Full Text] [Related]

  • 12. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
    Lapadula G.
    Reumatismo; 2005 Aug; 57(4 Suppl):22-9. PubMed ID: 16385352
    [Abstract] [Full Text] [Related]

  • 13. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.
    Jani M, Macphie E, Rao C, Moore S, Mirjafari H, McLoughlin Y, Chinoy H, Shah P.
    Clin Med (Lond); 2014 Feb; 14(1):95-6. PubMed ID: 24532765
    [No Abstract] [Full Text] [Related]

  • 15. Patient profiles in psoriatic disease: a case-based approach.
    Wiatrowski M, Furfaro N.
    Dermatol Nurs; 2007 Oct; Suppl():5-19; quiz 20-1. PubMed ID: 18341241
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.
    Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.
    Pharmacoeconomics; 2010 Oct; 28(10):935-45. PubMed ID: 20831302
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA, Symmons DP, Noyce PR, Ashcroft DM.
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.